Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study: https://t.co/ILQ1ywYhFP

Shares traded 28% higher on report of positive histological data across all Efruxifermin dosage groups.

$AKRO #NASH #hepatitis #healthcare #stocks https://t.co/2K5NZKGUla